Sleep Disorders Clinical Trial
— 174Official title:
PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)
The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.
Status | Completed |
Enrollment | 325 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year and older |
Eligibility |
Due to the design as an Observational Study no inclusion or exclusion criteria for therapy
are named. The included patient group is described under "Cohort / Group". Observational Criteria (=inclusion criteria for documentation): - Males and females - Children 1-12 years old - Adults >12 years old - suffering from nervous diseases, e.g. sleep disorders due to nervousness. Exclusion criteria for documentation: - children younger than 1 year - no nervous diseases, e.g. sleep disorders due to nervousness. - no treatment with PASCONAL NERVENTROPFEN |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Multiple German Practices | all over Germany |
Lead Sponsor | Collaborator |
---|---|
Pascoe Pharmazeutische Praeparate GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sumscore of 12 Individual Symptoms for Visit 1 (Baseline), Visit 2, and Visit 3 | The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints). | begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3) | No |
Primary | Nervousness/Restlessness for Visit 1 (Baseline), Visit 2, Visit 3 and Last Obsevation | The severity of nervousness/restlessness was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints). | begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3) | No |
Primary | Irritability/Eccentricity for Visit 1 (Baseline), Visit 2, Visit 3 and Last Observation | The severity of irritability/eccentricity was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints). | begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3) | No |
Primary | Tolerability After Visit 2 and Visit 3 | Assessment of tolerability at visit 2 and visit 3 well tolerated = no side effcts poor tolerated = side effects | appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3) | No |
Secondary | Changes of the Sum Score Between Baseline and Last Observation by Concomitant Medication and Treatment Duration | The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints). Decrease of the sumscore between baseline and last observation by concomitant medication (with and withour medication) and treatment duration (< 4 weeks and >= 4 weeks) |
begin (visit 1) and last obvservation (could be appr. after 2 weeks (visit 2) or 4 weeks (visit 3)) | No |
Secondary | Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Concomitant Medication | The symptom nervousness/restlessnesswas analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories "improved", "unchanged" and "worsened". For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was > 0). | begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3)) | No |
Secondary | Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Duration of Treatment | The symptom nervousness/restlessness was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories "improved", "unchanged" and "worsened". For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was > 0). | begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3)) | No |
Secondary | Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Concomitant Medication | The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories "improved", "unchanged" and "worsened". For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was > 0). | begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3)) | No |
Secondary | Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Duration of Treatment | The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories "improved", "unchanged" and "worsened". For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was > 0). | begin (visit 1) and last observation (appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3)) | No |
Secondary | Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Concomitant Medication (Yes/no) | Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication. The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories "PASCONAL® better", "No difference" and "PASCONAL® worse". |
appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3) | No |
Secondary | Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Treatment Duration | Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication. The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories "PASCONAL® better", "No difference" and "PASCONAL® worse". |
appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00163670 -
The Impact of Sleep Disorders on Motor Vehicle Accidents
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00203827 -
Pediatric Sleep Questionnaire: Use for Collection of Clinical Data
|
N/A | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Terminated |
NCT00750919 -
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
|
Phase 3 | |
Completed |
NCT03075241 -
Z-Drugs for Sleep Disorders in Alzheimer's Disease
|
Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT02585609 -
Sleep Quality in Patients With Advanced Cancer
|
N/A | |
Completed |
NCT03055156 -
Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms
|
N/A | |
Completed |
NCT01906866 -
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
|
Phase 3 | |
Completed |
NCT01929447 -
Evaluation of WP200 With the Unified Probe (WP200U)
|
N/A | |
Completed |
NCT02156128 -
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT01220401 -
Efficacy of a Brief Nightmare Treatment for Veterans
|
N/A | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Not yet recruiting |
NCT00749814 -
Sleep Disturbances in Hospitalized Children
|
Phase 4 | |
Completed |
NCT00518986 -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
|
Phase 4 |